PubMed:20973483 / 418-855 JSONTXT

{"project":"LitCoin-entities","denotations":[{"id":"8201","span":{"begin":23,"end":53},"obj":"ChemicalEntity"},{"id":"8202","span":{"begin":198,"end":217},"obj":"DiseaseOrPhenotypicFeature"},{"id":"8203","span":{"begin":228,"end":233},"obj":"OrganismTaxon"},{"id":"8204","span":{"begin":238,"end":241},"obj":"OrganismTaxon"},{"id":"8205","span":{"begin":252,"end":263},"obj":"ChemicalEntity"},{"id":"8206","span":{"begin":272,"end":281},"obj":"DiseaseOrPhenotypicFeature"},{"id":"8207","span":{"begin":283,"end":288},"obj":"OrganismTaxon"},{"id":"8208","span":{"begin":298,"end":307},"obj":"ChemicalEntity"},{"id":"8209","span":{"begin":316,"end":324},"obj":"DiseaseOrPhenotypicFeature"},{"id":"8210","span":{"begin":326,"end":329},"obj":"OrganismTaxon"},{"id":"8211","span":{"begin":330,"end":347},"obj":"ChemicalEntity"},{"id":"8212","span":{"begin":349,"end":355},"obj":"ChemicalEntity"},{"id":"8213","span":{"begin":400,"end":404},"obj":"ChemicalEntity"},{"id":"8214","span":{"begin":417,"end":422},"obj":"OrganismTaxon"}],"attributes":[{"id":"A5","pred":"db_id","subj":"8201","obj":"MESH:D058915"},{"id":"A6","pred":"db_id","subj":"8202","obj":"MESH:D010300"},{"id":"A7","pred":"db_id","subj":"8203","obj":"NCBITaxon:10090"},{"id":"A8","pred":"db_id","subj":"8204","obj":"NCBITaxon:10116"},{"id":"A9","pred":"db_id","subj":"8205","obj":"MESH:D006220"},{"id":"A10","pred":"db_id","subj":"8206","obj":"MESH:D002375"},{"id":"A11","pred":"db_id","subj":"8207","obj":"NCBITaxon:10090"},{"id":"A12","pred":"db_id","subj":"8208","obj":"MESH:D012110"},{"id":"A13","pred":"db_id","subj":"8209","obj":"MESH:D004409"},{"id":"A14","pred":"db_id","subj":"8210","obj":"NCBITaxon:10116"},{"id":"A15","pred":"db_id","subj":"8211","obj":"MESH:D016627"},{"id":"A16","pred":"db_id","subj":"8212","obj":"MESH:D016627"},{"id":"A17","pred":"db_id","subj":"8213","obj":"MESH:D015632"},{"id":"A18","pred":"db_id","subj":"8214","obj":"NCBITaxon:9606"}],"namespaces":[{"prefix":"_base","uri":"https://w3id.org/biolink/vocab/"},{"prefix":"MESH","uri":"http://id.nlm.nih.gov/mesh/"},{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id="},{"prefix":"NCBIGene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"OMIM","uri":"https://www.omim.org/entry/"},{"prefix":"DBSNP","uri":"https://www.ncbi.nlm.nih.gov/snp/"}],"text":"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model."}

{"project":"LitCoin-sentences","denotations":[{"id":"T4","span":{"begin":0,"end":437},"obj":"Sentence"}],"text":"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model."}

{"project":"LitCoin-entities-OrganismTaxon-PD","denotations":[{"id":"T1","span":{"begin":228,"end":233},"obj":"OrganismTaxon"},{"id":"T3","span":{"begin":238,"end":241},"obj":"OrganismTaxon"},{"id":"T5","span":{"begin":283,"end":288},"obj":"OrganismTaxon"},{"id":"T7","span":{"begin":326,"end":329},"obj":"OrganismTaxon"},{"id":"T9","span":{"begin":417,"end":422},"obj":"OrganismTaxon"},{"id":"T10","span":{"begin":423,"end":430},"obj":"OrganismTaxon"}],"attributes":[{"id":"A1","pred":"db_id","subj":"T1","obj":"NCBItxid:10090"},{"id":"A2","pred":"db_id","subj":"T1","obj":"NCBItxid:10088"},{"id":"A3","pred":"db_id","subj":"T3","obj":"NCBItxid:10116"},{"id":"A4","pred":"db_id","subj":"T3","obj":"NCBItxid:10114"},{"id":"A5","pred":"db_id","subj":"T5","obj":"NCBItxid:10090"},{"id":"A6","pred":"db_id","subj":"T5","obj":"NCBItxid:10088"},{"id":"A7","pred":"db_id","subj":"T7","obj":"NCBItxid:10116"},{"id":"A8","pred":"db_id","subj":"T7","obj":"NCBItxid:10114"},{"id":"A9","pred":"db_id","subj":"T9","obj":"NCBItxid:9606"},{"id":"A10","pred":"db_id","subj":"T10","obj":"NCBItxid:9443"}],"text":"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model."}

{"project":"LitCoin_Mondo","denotations":[{"id":"T3","span":{"begin":198,"end":217},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A3","pred":"mondo_id","subj":"T3","obj":"0005180"}],"text":"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model."}

{"project":"LitCoin-GeneOrGeneProduct-v0","denotations":[{"id":"T9","span":{"begin":23,"end":30},"obj":"GeneOrGeneProduct"},{"id":"T10","span":{"begin":34,"end":42},"obj":"GeneOrGeneProduct"},{"id":"T11","span":{"begin":43,"end":53},"obj":"GeneOrGeneProduct"},{"id":"T12","span":{"begin":81,"end":89},"obj":"GeneOrGeneProduct"},{"id":"T13","span":{"begin":125,"end":133},"obj":"GeneOrGeneProduct"},{"id":"T14","span":{"begin":264,"end":271},"obj":"GeneOrGeneProduct"},{"id":"T15","span":{"begin":308,"end":315},"obj":"GeneOrGeneProduct"},{"id":"T16","span":{"begin":357,"end":363},"obj":"GeneOrGeneProduct"},{"id":"T17","span":{"begin":378,"end":385},"obj":"GeneOrGeneProduct"},{"id":"T18","span":{"begin":400,"end":404},"obj":"GeneOrGeneProduct"}],"text":"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model."}

{"project":"LitCoin-GeneOrGeneProduct-v2","denotations":[{"id":"T3","span":{"begin":34,"end":42},"obj":"GeneOrGeneProduct"},{"id":"T4","span":{"begin":400,"end":404},"obj":"GeneOrGeneProduct"}],"text":"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model."}

{"project":"LitCoin-Disease-MeSH","denotations":[{"id":"T3","span":{"begin":198,"end":217},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":272,"end":281},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A3","pred":"originalLabel","subj":"T3","obj":"D010300"},{"id":"A4","pred":"originalLabel","subj":"T4","obj":"D002375"}],"text":"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model."}

{"project":"LitCoin-GeneOrGeneProduct-v3","denotations":[{"id":"T1","span":{"begin":400,"end":404},"obj":"GeneOrGeneProduct"}],"text":"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model."}

{"project":"LitCoin_Mondo_095","denotations":[{"id":"T3","span":{"begin":198,"end":217},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A3","pred":"mondo_id","subj":"T3","obj":"0005180"}],"text":"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model."}

{"project":"LitCoin-MeSH-Disease-2","denotations":[{"id":"T3","span":{"begin":198,"end":217},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":272,"end":281},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T5","span":{"begin":316,"end":324},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A3","pred":"ID:","subj":"T3","obj":"D010300"},{"id":"A4","pred":"ID:","subj":"T4","obj":"D002375"},{"id":"A5","pred":"ID:","subj":"T5","obj":"DISEASE"}],"text":"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model."}

{"project":"LitCoin-NCBITaxon-2","denotations":[{"id":"T1","span":{"begin":228,"end":233},"obj":"OrganismTaxon"},{"id":"T2","span":{"begin":238,"end":241},"obj":"OrganismTaxon"},{"id":"T3","span":{"begin":283,"end":288},"obj":"OrganismTaxon"},{"id":"T4","span":{"begin":326,"end":329},"obj":"OrganismTaxon"},{"id":"T5","span":{"begin":417,"end":422},"obj":"OrganismTaxon"},{"id":"T6","span":{"begin":423,"end":430},"obj":"OrganismTaxon"}],"text":"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model."}

{"project":"LitCoin-MONDO_bioort2019","denotations":[{"id":"T3","span":{"begin":198,"end":217},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":272,"end":281},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T5","span":{"begin":316,"end":324},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A3","pred":"#label","subj":"T3","obj":"D010300"},{"id":"A4","pred":"#label","subj":"T4","obj":"D002375"},{"id":"A5","pred":"#label","subj":"T5","obj":"DISEASE"}],"text":"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model."}

{"project":"LitCoin-Chemical-MeSH-CHEBI","denotations":[{"id":"T3","span":{"begin":252,"end":263},"obj":"ChemicalEntity"},{"id":"T5","span":{"begin":298,"end":307},"obj":"ChemicalEntity"},{"id":"T7","span":{"begin":330,"end":347},"obj":"ChemicalEntity"},{"id":"T9","span":{"begin":349,"end":355},"obj":"ChemicalEntity"},{"id":"T11","span":{"begin":400,"end":404},"obj":"ChemicalEntity"}],"attributes":[{"id":"A3","pred":"ID:","subj":"T3","obj":"D006220"},{"id":"A4","pred":"ID:","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_5613"},{"id":"A5","pred":"ID:","subj":"T5","obj":"D012110"},{"id":"A6","pred":"ID:","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_28487"},{"id":"A7","pred":"ID:","subj":"T7","obj":"D016627"},{"id":"A8","pred":"ID:","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_78741"},{"id":"A9","pred":"ID:","subj":"T9","obj":"D016627"},{"id":"A10","pred":"ID:","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_78741"},{"id":"A11","pred":"ID:","subj":"T11","obj":"D015632"},{"id":"A12","pred":"ID:","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_17963"}],"text":"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model."}

{"project":"LitCoin-training-merged","denotations":[{"id":"T11","span":{"begin":400,"end":404},"obj":"ChemicalEntity"},{"id":"T9","span":{"begin":349,"end":355},"obj":"ChemicalEntity"},{"id":"T7","span":{"begin":330,"end":347},"obj":"ChemicalEntity"},{"id":"T5","span":{"begin":298,"end":307},"obj":"ChemicalEntity"},{"id":"T3","span":{"begin":252,"end":263},"obj":"ChemicalEntity"},{"id":"T94575","span":{"begin":400,"end":404},"obj":"GeneOrGeneProduct"},{"id":"T72561","span":{"begin":316,"end":324},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":272,"end":281},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T39398","span":{"begin":198,"end":217},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T6","span":{"begin":423,"end":430},"obj":"OrganismTaxon"},{"id":"T2268","span":{"begin":417,"end":422},"obj":"OrganismTaxon"},{"id":"T91669","span":{"begin":326,"end":329},"obj":"OrganismTaxon"},{"id":"T99223","span":{"begin":283,"end":288},"obj":"OrganismTaxon"},{"id":"T36597","span":{"begin":238,"end":241},"obj":"OrganismTaxon"},{"id":"T99238","span":{"begin":228,"end":233},"obj":"OrganismTaxon"}],"attributes":[{"id":"A12","pred":"ID:","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_17963"},{"id":"A11","pred":"ID:","subj":"T11","obj":"D015632"},{"id":"A10","pred":"ID:","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_78741"},{"id":"A9","pred":"ID:","subj":"T9","obj":"D016627"},{"id":"A8","pred":"ID:","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_78741"},{"id":"A7","pred":"ID:","subj":"T7","obj":"D016627"},{"id":"A6","pred":"ID:","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_28487"},{"id":"A5","pred":"ID:","subj":"T5","obj":"D012110"},{"id":"A4","pred":"ID:","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_5613"},{"id":"A3","pred":"ID:","subj":"T3","obj":"D006220"},{"id":"A1971","pred":"#label","subj":"T72561","obj":"DISEASE"},{"id":"A30152","pred":"#label","subj":"T4","obj":"D002375"},{"id":"A10582","pred":"#label","subj":"T39398","obj":"D010300"}],"text":"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model."}

{"project":"PubmedHPO","denotations":[{"id":"T2","span":{"begin":198,"end":207},"obj":"HP_0001300"},{"id":"T3","span":{"begin":316,"end":324},"obj":"HP_0002304"}],"text":"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model."}